ME Oct 2023 3.000 call
| Previous close | 0.1100 |
| Open | 0.1500 |
| Bid | 0.1500 |
| Ask | 0.2000 |
| Strike | 3.00 |
| Expiry date | 2023-10-20 |
| Day's range | 0.1500 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 795 |
Motley FoolBetter Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Most biotechs don't have a diversified business model. Both 23andMe and Fulgent provide genetic testing and diagnostic services as well as perform drug development. The idea is that there's probably a competitive advantage of some kind in drug development, lurking somewhere in the reams of genetic information that the companies generate via their testing services.
Simply Wall St.Here's Why We're Not Too Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Yahoo Finance VideoWhy the human genome could be health care’s holy grail
23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe
Yahoo Finance23andMe CEO: We see more opportunities in DNA partnerships
23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.
Yahoo Finance Video3 things to watch at next week's Milken Conference
Yahoo Finance will have special coverage of the 2023 Milken Institute Global Conference, including live interviews, exclusive insights, and more. Brian Sozzi shares the 3 biggest things he's looking for at the Milken Conference this year: 1. Finance executives are set to address turmoil in the banking sector. 2. Top CEOs share their big ideas and predictions for the future. 3. Industry leaders from around the world will give us insight into the health of the global economy. Coverage begins Monday, May 1 from The Beverly Hilton Hotel in Los Angeles, California. Featured guests include Michael Milken, Citi (C) CEO Jane Fraser, Apollo (APO) CEO Marc Rowan, Mattel (MAT) CEO Ynon Kreiz, Mondelēz (MDLZ) CEO Dirk Van De Put, Former LinkedIn CEO Reid Hoffman, former SEC Commissioner Michael Piwowar, former Google (GOOGL) CEO Eric Schmidt, 23andMe (ME) CEO Anne Wojcicki and many others.
- Simply Wall St.
23andMe Holding Co.'s (NASDAQ:ME) Share Price Could Signal Some Risk
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...
- Simply Wall St.
23andMe Holding (NASDAQ:ME) shareholders have endured a 41% loss from investing in the stock a year ago
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
Motley Fool3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
The artificial intelligence (AI) revolution is here, and it's going to upend the biopharma sector in ways that most investors might not have considered. The end results are impossible to predict with accuracy, but based on what's possible with the AI tools of today, investors could reap tremendous returns from companies that are aggressive with implementing AI into their workflows. Specifically, there are at least three ways that AI is going to disrupt biotech stocks in the near term.
Motley FoolAI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
Artificial intelligence (AI) is all the rage these days, and given how rapidly the field is advancing, it's probably going to keep being the rage for quite some time -- potentially forever, if the evangelists are to be believed! While it's a bit tough to predict exactly what changes AI tools will bring about in our society, there are already quite a few businesses that are poised to benefit tremendously, and you've probably heard of some of them already. Let's examine two such companies to see how AI could power their future returns and help them compete.
Motley Fool2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
The long-term thesis for Viatris (NASDAQ: VTRS) rests on its drug pipeline, researching and developing generic copies of medicines that are off-patent, with the goal of getting regulators to agree that its generics are comparable to the branded drugs they seek to emulate. Its complex injectable generics, like Glucagon for hypoglycemic disorder, will be among the biggest growth segments, along with its new ophthalmology portfolio; each segment is expected to be worth more than $1 billion in annual revenue before the end of the decade.
BloombergAsia’s Richest Man Mukesh Ambani to Foray Into Genome Testing with $145 Kit
(Bloomberg) -- Billionaire Mukesh Ambani’s group is getting into genetic mapping, looking to make a health care trend led by disruptive US startups like 23andMe more affordable and widespread in India’s growing consumer market.Most Read from BloombergMeta Plans Thousands More Layoffs as Soon as This WeekUS Banks Are Finally Being Forced to Raise Rates on DepositsTrump’s Threat of a Third-Party Run Is Undercut by ‘Sore Loser’ LawsTesla Slashes Model S and X Prices for the Second Time This YearHol
Motley Fool2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
Wall Street analysts are expecting that 23andMe's (NASDAQ: ME) stock will hit around $5.69 within a year, which means they think it can grow to more than double its current price of $2.61. In 2019, it reported sales of $156.3 million, which means that its compound annual growth rate (CAGR) from 2019 through 2024 would be 31.3%.
Motley FoolThis Genetics Stock Could Have Massive Long-Term Potential
Genetics company 23andMe (NASDAQ: ME) hasn't exactly been a strong performer, with shares down by about 73% since it went public via a special purpose acquisition company (SPAC). The company recently reported stronger results than analysts had been expecting and it has a massive pipeline of opportunities in the works. 23andMe is best known for its consumer genetics testing, but it also offers subscription products and telehealth services.
- Simply Wall St.
23andMe Holding Third Quarter 2023 Earnings: Beats Expectations
23andMe Holding ( NASDAQ:ME ) Third Quarter 2023 Results Key Financial Results Revenue: US$66.9m (up 18% from 3Q 2022...
Motley Fool3 Penny Stocks That Could Make You Filthy Rich
The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Although these names are still exceedingly high-risk, I think aggressive investors may want to consider buying shares of Precigen (NASDAQ: PGEN), Rigel Pharmaceuticals (NASDAQ: RIGL), and 23andMe Holding Company (NASDAQ: ME) right now. Read on to find out why these three low-priced equities might be a tremendous wealth escalator for patient shareholders.
- Simply Wall St.
Institutional investors own a significant stake of 37% in 23andMe Holding Co. (NASDAQ:ME)
If you want to know who really controls 23andMe Holding Co. ( NASDAQ:ME ), then you'll have to look at the makeup of...
Yahoo Finance VideoTelehealth: ‘There’s a real opportunity’ for investment, 23andMe founder says
23andMe Co-Founder and CEO Anne Wojcicki sits down with Yahoo Finance’s Anjalee Khemlani at the HLTH conference to discuss the slowdown in growth, consolidation in the health care space, the company’s partnership with GSK, drug discovery, and more.
Motley Fool2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
They're both using unique and highly efficient approaches to developing and deploying their medicines.
- Simply Wall St.
Shareholders in 23andMe Holding (NASDAQ:ME) are in the red if they invested a year ago
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
Motley Fool3 Reasons You Should (Still) Be Buying Growth Stocks Right Now
With the market down by more than 22% this year, we're falling deeper into the bear market, and growth stocks are leading the descent. Rather than panic selling some of your growth stocks or refusing to consider them altogether, it's probably in your best interest to be a net buyer, even if the market continues to drop. On average, bear markets last for a year, give or take a month or so.
Yahoo Finance VideoInfluencers with Andy Serwer: Deb Liu
In this episode of Influencers, Andy is joined by Ancestry CEO Deb Liu, as they discuss the business of genomics, Deb's experience managing some of the top products at Facebook, and her plan to make Silicon Valley more accessible to women.
Yahoo Finance VideoAncestry CEO on 23andMe: ‘I think their product is really incredible’
Ancestry CEO Deb Liu joins 'Influencers with Andy Serwer' to discuss the business of DNA and how Ancestry.com competes with other genealogy products.
- Simply Wall St.
One 23andMe Holding Co. (NASDAQ:ME) insider upped their stake in the previous year
Looking at 23andMe Holding Co.'s ( NASDAQ:ME ) insider transactions over the last year, we can see that insiders were...
- Motley Fool
2 Ex-SPACs I Wouldn't Touch Right Now
Hundreds of businesses went public during the SPAC boom of 2020 and 2021, and to be fair, some of them are doing quite well and delivering for investors. Two in particular I'd stay away from right now are property technology company Latch (NASDAQ: LTCH) and genetics business 23andMe (NASDAQ: ME). Both are losing money at an alarming pace and don't have clear paths to profitability, which isn't exactly a good combination in today's economic climate.
- Motley Fool
Despite Some Big Losers, These Growth Stocks Are Keeping the Nasdaq Bull Market Going
Investors continue to slowly move away from worries about the economy, inflation, and interest rates, sending growth stocks higher. It's not all good news and positivity, though.